Outlook Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Dec 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 19, 2025
OTLK$0.46+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Deficit
| · · · · · · · · · · · · · · | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Stockholders’ Deficit | |||||||||||||
| · · Common Stock · · Additional · · Accumulated · · Total Stockholders’ | |||||||||||||
| · · Shares · · Amount · · Paid-in Capital · · Deficit · · Deficit | |||||||||||||
| Balance at October 1, 2023 | 13,012,833 | | $130,128 | | $453,350,281 | | $(467,918,186) | | $(14,437,777) | ||||
| Issuance of common stock in connection with conversion of convertible promissory note | 1,607,093 | | | 16,072 | | | 11,233,928 | | | — | | | 11,250,000 |
| Sale of common stock, net of issuance costs (Note 10) | 9,285,709 | | | 92,857 | | | — | | | — | | | 92,857 |
| Stock-based compensation expense | — | | | — | | | 5,385,124 | | | — | | | 5,385,124 |
| Net loss | — | | | — | | | — | | | (75,366,714) | | | (75,366,714) |
| Balance at September 30, 2024 | 23,905,635 | | | 239,057 | | | 469,969,333 | | | (543,284,900) | | | (73,076,510) |
| Issuance of common stock and common stock warrants in connection with exercise of common stock warrants | 10,896,779 | | | 108,967 | | | 66,752,003 | | | — | | | 66,860,970 |
| Issuance of common stock in connection with conversion of convertible promissory note | 1,117,252 | | | 11,173 | | | 2,513,827 | | | — | | | 2,525,000 |
| Sale of common stock, net of issuance costs (Note 10) | 17,967,567 | | | 179,676 | | | 24,850,179 | | | — | | | 25,029,855 |
| Stock-based compensation expense | — | | | — | | | 8,897,887 | | | — | | | 8,897,887 |
| Net loss | — | | | — | | | — | | | (62,424,863) | | | (62,424,863) |
| Balance at September 30, 2025 | 53,887,233 | $538,873 | $572,983,229 | $(605,709,763) | $(32,187,661) | ||||||||
See accompanying notes to consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.